China Exemestane Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Exemestane Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
According to the publisher’s market research, Pharmacia & Upjoin’s exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002.
Pharmacia &Upjoin’s exemestane (trade name AROMASIN) is extremely competitive in the Chinese market, accounting for more than 90% of China’s exemestane market in 2020 in terms of sales value.
Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.
Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer.
The publisher expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.
Topics Covered:
- Impact of COVID-19 on China’s Exemestane Market
- Development Environment of Exemestane in China
- Sales Volume of Exemestane in China
- Sales Volume and Value of Exemestane in China by Region
- Major Exemestane Manufacturers in China and Their Market Shares
- Sales Price of Exemestane in China
- Prospects of China’s Exemestane Market, 2021-2025
Key Topics Covered:
1 Relevant Concepts of Exemestane
1.1 Indications of Exemestane
1.2 Development of China’s Exemestane Market
1.3 Governmental Approval of Exemestane in China
1.4 The Impact of COVID-19 on China’s Exemestane Market
2 Sales of Exemestane in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Exemestane in China by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Capsules
3 Analysis of Major Exemestane Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Pharmacia & Upjohn SpA
3.2.1 Company Profile
3.2.2 Sales of Exemestane in China
3.3 Qilu Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Exemestane in China
3.4 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 Sales of Exemestane in China
3.5 Tongfang Pharmaceutical Group Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Exemestane in China
4 Sales Price of Exemestane of Different Companies in China, 2020-2021
4.1 Pharmacia & Upjohn SpA (AROMASIN)
4.2 Qilu Pharmaceutical Co., Ltd. (SuLai)
4.3 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd. (YiSiTan)
4.4 Tongfang Pharmaceutical Group Co., Ltd. (YouKeYi)
5 Prospects of China’s Exemestane Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/mcr0j0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Recent Posts
“One Earth Summit” 2025 Held Successfully Hong Kong Fully Leverages Its Role as an International Financial Center and Leader in Green Finance
Laying a Solid Foundation for the Development of ESG Investment and Green Innovation Calling for…
The Campaign “It’s Time for EU Beef” is coming to Cebu and Manila in April
The Philippine meat industry will be shown the quality and guarantees of European beef MANILA,…
European beef will continue to play aleading role in Singapore in the coming months of 2025
"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the…
Make Waves at Galaxy Macau: Dive into a Luxurious One-Stop Ultimate Holiday Escape with the Reopening of the Grand Resort Deck
MACAU SAR - Media OutReach Newswire - 27 March 2025 - The world-class luxurious Galaxy…
Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
In an effort to achieve a target of 80% of patients controlling the three highs…
Li Ning Company Limited Announces 2024 Annual Results
Strengthen the “Single Brand, Multi-Categories, Diversified Channels” Strategy | Solidify Brand and Product Competitiveness, Ensure…